Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival. Inclusive of the common ER presentation, surgery, diagnostics/staging, and chemotherapy, HSA impacts numerous specialty services throughout a hospital and accordingly the unmet needs are recognized by all parts of the profession. Through Discovery’s previous work in hemangiosarcoma (CHAMP; Canine Hemangiosarcoma Molecular Profiling study) we now have new knowledge in HSA that allows truly innovative trials investigating its diagnosis, prognosis, and treatment. Furthermore, the collective data obtained from these planned studies will provide significant translational benefit for humans affected with a similar cancer, angiosarcoma.
Our Programs and Priorities
The scientific priorities of Ethos Discovery emerge from our understanding of unmet diagnostic and scientific needs and have been strategically developed as integrated multi-study programs. These programs allow Discovery to achieve focus in these areas of unmet need while also allowing for new opportunities to be considered within a cohesive strategy that will help both human and pet animal patients. Our scientific programs and their corresponding studies are outlined below.
Ongoing Clinical Trials at Ethos Discovery:
Ethos Veterinary Health hospitals provide state-of-the-art clinical care to pets with complex medical problems in the setting of multi-specialty veterinary services.
The scientific strategy of Ethos Discovery focuses on identifying areas of unmet need through the optics of clinical teams within Ethos Veterinary Health. These hospitals provide access to clinical trials to patients with naturally occurring disease.